This study points to the need for further preclinical studies and clinical trials, and consistently, favorable treatment response was observed in patients with HER2-targeted amplification cancer in clinical trials; this study increases the feasibility of the HER2-targeted CRC treatment strategy (Mangiapane et al., 2022). This evidence concerns the gene ERBB2 and colorectal carcinoma.